A polypeptide termed oncostatin M, which inhibits the replication of A375 melanoma and other human tumor cells, but not normal human fibroblasts, has been isolated from serum-free supernatants of U-937 histiocytic lymphoma cells that have been induced to differentiate into macrophage-like cells following treatment with the phorbol ester phorbol 12-myristate 13-acetate. No such growth inhibitory activity is detected in the supernatant of untreated U-937 cells, indicating that the protein is induced or increased in expression in the phorbol ester-induced differentiated cells. Oncostatin M is stable between pH 2 and 11 and after heating for 1 hr at 560C but is not stable at 90TC. Purification of oncostatin M has been achieved by gel chromatography and reversed-phase HPLC, using sequentially acetonitrile and n-propanol in the presence of aqueous trifluoroacetic acid. The apparent molecular weight of oncostatin M is -18,000, as determined by gel chromatography, and 28,000, as determined by polyacrylamide gel electrophoresis. (vol/vol) fetal bovine serum, L-glutamine, and penicillin-streptomycin. All of the following cell lines were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (vol/vol) fetal bovine serum, L-glutamine, and penicillin-streptomycin. The A375 cell line was derived from a human melanoma (26); A549, from a lung carcinoma (26); HTB10, from a neuroblastoma (27); SK-MEL-28, from a melanoma (28); and WI-26 and WI-38 cells were derived from human embryonic lung (29, 30) .
oncostatin M and other proteins was found, including other tumor cell inhibitory proteins produced by mononuclear cells. Oncostatin M, therefore, appears to represent a distinct cell growth regulator.
Mononuclear cells including T cells, natural killer cells, and macrophages have been shown to inhibit growth of cells of many different tumors (1) (2) (3) (4) (5) (6) either by direct contact or by soluble factors they produce. There has been considerable effort expended to elucidate factors produced by mononuclear cells that can directly inhibit tumor cell replication and/or can augment T-cell immune responses or natural killer cell and macrophage activity against tumors. Mononuclear cell-derived factors with such activities include the interferons (for review see ref. 7) , tumor necrosis factor (8-10), lymphotoxin (11, 12) , type ,B transforming growth factor (13) , interleukin 1 (14) (15) (16) (17) (18) (19) , interleukin 2 (for review see ref. 20) , leukoregulin (21) , and some less well-defined factors (22, 23) . Since each of these factors have different spectra of activities and may interact differently in conjunction with other factors, there remains a strong interest in isolating and characterizing additional factors that could be used to suppress tumor growth. Following treatment of the U-937 histiocytic lymphoma cell line (24) with the phorbol ester phorbol 12-myristate 13-acetate (PMA), growth is inhibited, and the cells are induced to differentiate, expressing cell surface markers, enzymes, and activities such as the phagocytic activity associated with macrophages (25) . We have thus undertaken studies aimed at isolating, purifying, and characterizing tumor inhibitory factors produced by these macrophage-like cells. We report here that PMA-treated U-937 cells release a polypeptide that inhibits the growth of A375 melanoma and other tumor cells, but augments the growth of normal fibroblasts. This factor, termed oncostatin M, has been purified by gel chromatography and reversed-phase HPLC and appears to be a distinct cell growth regulator based on its amino-terminal amino acid sequence and its biological activities.
MATERIALS AND METHODS
Cell Lines and Propagation. All cell lines used were of human origin. U-937 cells, derived from a histiocytic lymphoma (24) , were grown in RPMI 1640 medium with 10% (vol/vol) fetal bovine serum, L-glutamine, and penicillin-streptomycin. All of the following cell lines were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (vol/vol) fetal bovine serum, L-glutamine, and penicillin-streptomycin. The A375 cell line was derived from a human melanoma (26) ; A549, from a lung carcinoma (26) ; HTB10, from a neuroblastoma (27) ; SK-MEL-28, from a melanoma (28) ; and WI-26 and WI-38 cells were derived from human embryonic lung (29, 30) .
Cell Growth Inhibition Assay. The assay was performed in flat 96-well plates (3596; Costar, Cambridge, MA). Human A375 melanoma cells were used as a sensitive indicator cell line. Cells (3 x The final purification of oncostatin M was achieved by reversed-phase HPLC. The separations were performed on a 1LBondapak C18 column (10-,im particle size, 7.8 x 300 mm; Waters) at room temperature. The primary mobile phase was 0.1% CF3COOH, and the secondary mobile phase was acetonitrile containing 0.1% CF3COOH. The concentration of acetonitrile was increased linearly (0.1% per min) during iS0 min at a flow rate of 2.0 ml/min at room temperature for elution of proteins. Oncostatin M-containing fractions were rechromatographed on an analytical gBondapak-C18 column (3.9 x 300 mm), using acetonitrile for elution of proteins, and rechromatographed on the same column, with n-propanol containing 0.1% CF3COOH as the mobile-phase modifier. The n-propanol concentration was increased linearly (0.05% per min) during 4 hr at a flow rate of 0.5 ml/min.
Amino Acid Sequence Determination of Oncostatin M. For amino-terminal amino acid sequence analysis, oncostatin M (1.6 ,ug) was reduced with 20 mM dithiothreitol in 100 jLI of 0.4 M Tris.HCl/6 M guanidine HCl/0.1% Na2EDTA, pH 8.5, for 2 hr at 50°C and subsequently S-carboxamidomethylated with 45 Purification of Oncostatin M. A summary of the steps leading to the isolation and recovery of oncostatin M is presented in Table 2 . The supernatant of the PMA-treated U-937 cells was concentrated, dialyzed against 1 M acetic acid, and lyophilized, and the acid-soluble oncostatin M containing crude material was subjected to gel chromatography (Fig. 1) . A major peak of anti-proliferative activity against A375 cells, with an apparent molecular weight of 18,000, was found.
Oncostatin M was further purified by reversed-phase HPLC. The biologically active fractions, after gel chromatography, were diluted 1:2 with 0.1% CF3COOH, and then chromatographed on a preparative ,Bondapak C18 column. A typical elution pattern is illustrated in Fig. 2A . GIA of individual fractions was determined and the four fractions with peak activity were taken for rechromatography on an analytical ,uBondapak C18 column (Fig. 2B) . Oncostatin M eluted at approximately 41% (vol/vol) acetonitrile. A 140-fold purification after gel chromatography was obtained.
Rechromatography of the biologically active fractions on 1LBondapak support was chosen for the final two purification steps using n-propanol as the organic solvent for the elution of peptides. A typical elution pattern is shown in Fig. 2C . Rechromatography of the active fraction, using more shallow gradient conditions, is shown in Fig. 2D . GIA copurified with a distinct absorbance peak. Oncostatin M was eluted from a ,uBondapak C18 column at =26% (vol/vol) n-propanol. The purification of oncostatin M was -3500-fold with a yield of 8% of the initial total GIA. The overall recovery of oncostatin M from the gel permeation step through the final reversed- Fig. 2 A, B, C, and D Fig. 3 .
The partial amino acid sequence of oncostatin M was compared with each known sequence stored in the protein ogies with any other known sequence including those of other proteins with anti-tumor activity that are produced by mononuclear cells, namely the interferons (38-44), tumor necrosis factor (12), various proteins with interleukin 1 activity (16, 18, 19) , lymphotoxin (12), or type ,B transforming growth factor (45).
NaDodSO4/PAGE Analysis of Oncostatin M. Purified oncostatin M, subjected to NaDodSO4/PAGE performed under reducing conditions, was found to have an apparent molecular weight of %28,000 (Fig. 4) . The band was excised from the gel, electroeluted, electrodialyzed, and found to have the same amino-terminal amino acid sequence as that shown in Fig. 3 . Oncostatin M, subjected to PAGE under nonreducing conditions, also has an apparent molecular weight of28,000, and protein electroeluted from the band was found to inhibit proliferation of A375 cells (data not shown). Biological Characterization of Oncostatin M. As shown in First, highly purified oncostatin M was found not to inhibit proliferation of mouse L-929 cells, the prototype tumor necrosis factor-sensitive cell line (8-10), whereas crude supernatant from PMA-treated U-937 cells had anti-proliferative activity against L-929 cells. However, at concentrations of tumor necrosis factor that inhibited replication of L-929 cells by 99%, no inhibition of A375 cell growth was observed. A375 melanoma cells have also been reported by others (17) to be resistant to the anti-proliferative activity of human tumor necrosis factor. The lack of cytotoxic activity against L-929 cells, together with the amino-terminal amino acid sequence, suggests that oncostatin M is not related to tumor necrosis factor or lymphotoxin (12) . Second, although interleukin 1 has been reported to be produced by U-937 cells (19) and to inhibit replication of A375 cells (17) , oncostatin M, at concentrations up to 50 GIA units/ml, lacked interleukin 1 activity as measured by augmentation of mouse thymocyte proliferation (data not shown). Third, type (3 transforming growth factor inhibits A375 melanoma cells and mink lung cells; however, oncostatin M only minimally effected the replication of mink lung cells compared to its marked inhibitory activity for A375 cells. Furthermore, whereas type P3 transforming growth factor is resistant to heating at 90°C, activity of oncostatin M is lost at 90°C. Fourth, interferons-a, The biological assay used to purify oncostatin M depended on its ability to inhibit the replication of a human tumor cell line. Other peptides with an analogous property such as the interferons, interleukins, and tumor necrosis factor have multiple, diverse biological activities when tested in vivo. We would expect the same to be the case for oncostatin M.
